Alarming Rise in Breast and Cervical Cancers in Low- and Middle-Income Countries: Breaking Down Screening Barriers

By HEOR Staff Writer

July 5, 2023

Breast and cervical cancers are on the rise in low- and middle-income countries, with lower cure rates due to late diagnosis. Screening programs in these countries are not comprehensive, hindering early detection. 

By analysing studies published between 2016 and 2021, articles from low- and middle-income countries and using the 5A framework (approachability, acceptability, availability, affordability, and appropriateness), screening barriers were classified. 

Findings highlighted the lack of awareness, high screening costs, and distance to screening centers as major obstacles. Embarrassment, fear, and cultural factors also contribute to low screening rates. 

To combat these challenges, policymakers and governments must take action to enhance public confidence in healthcare systems. Evidence-based strategies are needed to educate women about cancer causes and risk factors, promoting increased adherence to screening. Together, we can make a difference in the fight against breast and cervical cancers worldwide.

Reference url

Recent Posts

European Immunotherapy Approval for Ovarian Cancer: KEYTRUDA’s New Role in Treating PD-L1-P...

By HEOR Staff Writer

April 6, 2026

Immunotherapy ovarian cancer treatment has taken a major step forward in Europe. The European Commission has approved KEYTRUDA (pembrolizumab) in combination with paclitaxel, with or without bevacizumab, for adults with PD-L1 CPS ≥1 platinum-resistant recurrent ovarian, fallopian tube, or primary...
Advancements in Immunotherapy for Hepatocellular Carcinoma: EMERALD-3 Trial Results

By João L. Carapinha

April 3, 2026

Immunotherapy hepatocellular carcinoma treatment has taken a significant step forward with positive high-level results from the EMERALD-3 Phase III trial. The addition of dual immunotherapy using AstraZeneca’s STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab) together with lenvatin...
Facilitating Reimbursement for Intravesical Gemcitabine in Bladder Cancer Treatment
Reimbursement Bladder Cancer advances with the assignment of a permanent HCPCS J-code for INLEXZO™ (gemcitabine intravesical system), effective April 1, 2026. This standardized billing code simplifies reimbursement bladder cancer treatment for adult patients with BCG-unresponsive non-muscle invas...